Literature DB >> 27745736

Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae.

Kenneth P Smith1, James E Kirby2.   

Abstract

We evaluated activity of apramycin, a non-ototoxic/non-nephrotoxic aminocyclitol against 141 clinical Enterobacteriaceae isolates, 51% of which were non-susceptible to carbapenems (CRE). Among CRE, 70.8% were apramycin susceptible, which compared favorably to aminoglycosides in current clinical use. Our data suggest that apramycin deserves further investigation as a repurposed, anti-CRE therapeutic.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activity spectrum; Aminoglycoside; Apramycin; Carbapenem-resistant Enterobacteriaceae; Multidrug-resistance; Repurposing

Mesh：

Substances：

Year:  2016        PMID： 27745736     DOI： 10.1016/j.diagmicrobio.2016.09.002

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  20 in total

1.  Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics.

Authors:  Amr Sonousi; Vikram A Sarpe; Margarita Brilkova; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich
Journal:  ACS Infect Dis       Date:  2018-05-10       Impact factor: 5.084

2.  Aminoglycosides: Time for the Resurrection of a Neglected Class of Antibacterials?

Authors:  Erik C Böttger; David Crich
Journal:  ACS Infect Dis       Date:  2019-12-19       Impact factor: 5.084

Review 3.  Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.

Authors:  Yoshiaki Takahashi; Masayuki Igarashi
Journal:  J Antibiot (Tokyo)       Date:  2017-10-25       Impact factor: 2.649

4.  Synthesis of saccharocin from apramycin and evaluation of its ribosomal selectivity.

Authors:  Vikram A Sarpe; Michael G Pirrone; Klara Haldimann; Sven N Hobbie; Andrea Vasella; David Crich
Journal:  Medchemcomm       Date:  2019-03-13       Impact factor: 3.597

5.  Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.

Authors:  Stefan Riedel; Divya Vijayakumar; Gretchen Berg; Anthony D Kang; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

6.  Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.

Authors:  Anthony D Kang; Kenneth P Smith; Anders H Berg; Katherine A Truelson; George M Eliopoulos; Christopher McCoy; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant.

Authors:  Jonathan C K Quirke; Parasuraman Rajasekaran; Vikram A Sarpe; Amr Sonousi; Ivan Osinnii; Marina Gysin; Klara Haldimann; Qiao-Jun Fang; Dimitri Shcherbakov; Sven N Hobbie; Su-Hua Sha; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich
Journal:  J Am Chem Soc       Date:  2019-12-17       Impact factor: 15.419

8.  Characterization of 16S rRNA methylase genes in Enterobacterales and Pseudomonas aeruginosa in Athens Metropolitan area, 2015-2016.

Authors:  Konstantina Nafplioti; Maria Souli; Panagiota Adamou; Eleni Moraitou; Panagiota Giannopoulou; Paraskevi Chra; Maria Damala; Evangelos Vogiatzakis; Eleftheria Trikka-Graphakos; Vasiliki Baka; Eleni Prifti; Anastasia Antoniadou; Irene Galani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-08-14       Impact factor: 3.267

9.  Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.

Authors:  Katherine A Truelson; Thea Brennan-Krohn; Kenneth P Smith; James E Kirby
Journal:  Diagn Microbiol Infect Dis       Date:  2018-05-29       Impact factor: 2.803

Review 10.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.